Cardiac structure and function after revascularization versus medical therapy for renal artery stenosis: the ASTRAL heart echocardiographic sub-study.


Journal

BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793

Informations de publication

Date de publication:
14 06 2019
Historique:
received: 19 12 2017
accepted: 30 05 2019
entrez: 16 6 2019
pubmed: 16 6 2019
medline: 30 9 2020
Statut: epublish

Résumé

The ASTRAL trial showed no difference in clinical outcomes between medical therapy and revascularization for atherosclerotic renal vascular disease (ARVD). Here we report a sub-study using echocardiography to assess differences in cardiac structure and function at 12 months. ASTRAL patients from 7 participating centres underwent echocardiography at baseline and 12 months after randomisation. Changes in left ventricular ejection fraction (LVEF), left ventricular mass (LVM), left atrial diameter (LAD), aortic root diameter (AoRD), E:A, and E deceleration time (EDT) were compared between study arms. Analyses were performed using t-tests and multivariate linear regression. Ninety two patients were included (50 medical versus 42 revascularization). There was no difference between arms in any baseline echocardiographic parameter. Comparisons of longitudinal changes in echocardiographic measurements were: δLVEF medical 0.8 ± 8.7% versus revascularization - 2.8 ± 6.8% (p = 0.05), δLVM - 2.9 ± 33 versus - 1.7 ± 39 g (p = 0.9), δLAD 0.1 ± 0.4 versus 0.01 ± 0.5 cm (p = 0.3), δAoRD 0.002 ± 0.3 versus 0.06 ± 0.3 cm (p = 0.4), δE:A - 0.0005 ± 0.6 versus 0.03 ± 0.7 (p = 0.8), δEDT - 1.1 ± 55.5 versus - 9.0 ± 70.2 ms (p = 0.6). In multivariate models, there were no differences between treatment groups for any parameter at 12 months. Likewise, change in blood pressure did not differ between arms (mean δsystolic blood pressure medical 0 mmHg [range - 56 to + 54], revascularization - 3 mmHg [- 61 to + 59], p = 0.60). This sub-study did not show any significant differences in cardiac structure and function accompanying renal revascularization in ASTRAL. Limitations include the small sample size, the relative insensitivity of echocardiography, and the fact that a large proportion of ASTRAL patient population had only modest renal artery stenosis as described in the main study.

Sections du résumé

BACKGROUND
The ASTRAL trial showed no difference in clinical outcomes between medical therapy and revascularization for atherosclerotic renal vascular disease (ARVD). Here we report a sub-study using echocardiography to assess differences in cardiac structure and function at 12 months.
METHODS
ASTRAL patients from 7 participating centres underwent echocardiography at baseline and 12 months after randomisation. Changes in left ventricular ejection fraction (LVEF), left ventricular mass (LVM), left atrial diameter (LAD), aortic root diameter (AoRD), E:A, and E deceleration time (EDT) were compared between study arms. Analyses were performed using t-tests and multivariate linear regression.
RESULTS
Ninety two patients were included (50 medical versus 42 revascularization). There was no difference between arms in any baseline echocardiographic parameter. Comparisons of longitudinal changes in echocardiographic measurements were: δLVEF medical 0.8 ± 8.7% versus revascularization - 2.8 ± 6.8% (p = 0.05), δLVM - 2.9 ± 33 versus - 1.7 ± 39 g (p = 0.9), δLAD 0.1 ± 0.4 versus 0.01 ± 0.5 cm (p = 0.3), δAoRD 0.002 ± 0.3 versus 0.06 ± 0.3 cm (p = 0.4), δE:A - 0.0005 ± 0.6 versus 0.03 ± 0.7 (p = 0.8), δEDT - 1.1 ± 55.5 versus - 9.0 ± 70.2 ms (p = 0.6). In multivariate models, there were no differences between treatment groups for any parameter at 12 months. Likewise, change in blood pressure did not differ between arms (mean δsystolic blood pressure medical 0 mmHg [range - 56 to + 54], revascularization - 3 mmHg [- 61 to + 59], p = 0.60).
CONCLUSIONS
This sub-study did not show any significant differences in cardiac structure and function accompanying renal revascularization in ASTRAL. Limitations include the small sample size, the relative insensitivity of echocardiography, and the fact that a large proportion of ASTRAL patient population had only modest renal artery stenosis as described in the main study.

Identifiants

pubmed: 31200662
doi: 10.1186/s12882-019-1406-y
pii: 10.1186/s12882-019-1406-y
pmc: PMC6570952
doi:

Types de publication

Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

220

Subventions

Organisme : Medical Research Council
Pays : United Kingdom

Références

Blood Press. 1999;8(3):141-50
pubmed: 10595691
Hypertension. 2000 Jun;35(6):1183-8
pubmed: 10856260
Am Heart J. 2002 Jul;144(1):115-21
pubmed: 12094197
Circulation. 2002 Oct 22;106(17):2194-9
pubmed: 12390947
Eur J Heart Fail. 2003 Oct;5(5):679-91
pubmed: 14607208
Circulation. 2004 Sep 14;110(11):1456-62
pubmed: 15326072
Nephrol Dial Transplant. 2005 Aug;20(8):1604-9
pubmed: 15870215
Eur Heart J. 2005 Aug;26(16):1596-605
pubmed: 15919719
Kidney Int. 2005 Jul;68(1):293-301
pubmed: 15954920
J Am Soc Nephrol. 2005 Sep;16(9):2746-53
pubmed: 16049071
J Am Coll Cardiol. 2006 Mar 21;47(6):1239-312
pubmed: 16545667
Am J Cardiol. 2006 Aug 1;98(3):383-5
pubmed: 16860028
J Endovasc Ther. 2007 Apr;14(2):189-97
pubmed: 17488176
Lancet. 2007 Jun 23;369(9579):2079-87
pubmed: 17586303
Am J Cardiol. 2007 Jul 15;100(2):273-9
pubmed: 17631082
N Engl J Med. 2009 Nov 12;361(20):1953-62
pubmed: 19907042
Cardiovasc Ther. 2011 Aug;29(4):e6-21
pubmed: 20370792
Nephrol Dial Transplant. 2012 Apr;27(4):1403-9
pubmed: 21993376
Nephrol Dial Transplant. 2013 Feb;28(2):479-83
pubmed: 22262735
Am J Kidney Dis. 2012 Jul;60(1):39-46
pubmed: 22495466
Am J Kidney Dis. 2014 Feb;63(2):186-97
pubmed: 24074824
N Engl J Med. 2014 Jan 2;370(1):13-22
pubmed: 24245566
J Am Coll Cardiol. 2014 Jul 22;64(3):247-52
pubmed: 25034059
Catheter Cardiovasc Interv. 2014 Dec 1;84(7):1163-71
pubmed: 25138644
J Am Soc Hypertens. 2016 Feb;10(2):149-158.e3
pubmed: 26778771
J Am Soc Echocardiogr. 1989 Sep-Oct;2(5):358-67
pubmed: 2698218
Nephrol Dial Transplant. 2017 Jun 1;32(6):1006-1013
pubmed: 27257278
Nephrology (Carlton). 2018 May;23(5):411-417
pubmed: 28240799
Nephrol Dial Transplant. 2018 Mar 1;33(3):497-506
pubmed: 28371854
Int J Cardiovasc Imaging. 2017 Nov;33(11):1711-1721
pubmed: 28685313
Lancet. 1993 Jun 12;341(8859):1521-2
pubmed: 8099389
Hypertension. 1996 Mar;27(3 Pt 1):319-23
pubmed: 8698432

Auteurs

Darren Green (D)

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK. darrengreen@doctors.org.uk.

Diana Vassallo (D)

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Kelly Handley (K)

University of Birmingham, Birmingham, UK.

Natalie Ives (N)

University of Birmingham, Birmingham, UK.

Keith Wheatley (K)

University of Birmingham, Birmingham, UK.

Constantina Chrysochou (C)

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Janet Hegarty (J)

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Julian Wright (J)

Manchester Foundation Trust, Manchester, UK.

Jon Moss (J)

Western Infirmary, Glasgow, UK.

Rajan K Patel (RK)

Western Infirmary, Glasgow, UK.

Chris Deighan (C)

Glasgow Royal Infirmary, Glasgow, UK.

John Webster (J)

Aberdeen Royal Infirmary, Aberdeen, UK.

Peter Rowe (P)

Derriford Hospital, Plymouth, UK.

Sue Carr (S)

University Hospitals of Leicester, Leicester, UK.

Jenny Cross (J)

Royal Free Hospital, London, UK.

Jamie O'Driscoll (J)

St George's Hospital, London, UK.

Raj Sharma (R)

St George's Hospital, London, UK.

Patrick Mark (P)

Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow, UK.

Philip A Kalra (PA)

Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH